2026-10-26 12:58:29 UTC#514786newconfirmedpress release
MNOV stock news
MNOV stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire17 wire items
2026-10-22 11:13:21 UTC#499460newconfirmedpress release
Medicenna Therapeutics to present preclinical data on MDNA209 at Treg and Interleukin-2 Therapies conference
2026-10-12 10:00:00 UTC#445747newconfirmednews
MediciNova MN-001 Phase 2 trial misses primary endpoints in NAFLD study; ALS data expected year-end
2026-10-12 10:00:00 UTC#445742newconfirmedpress release
MediciNova CEO provides shareholder update on MN-001 Phase 2 clinical trial progress
2026-10-05 13:14:42 UTC#413666newconfirmedpress release
Medicenna to present ABILITY-1 Phase 1/2 study topline data for MDNA11 at SITC 2026
financial postimportance 0.40trust 0.90Medicenna Therapeutics Corp. +0.30MDNA11 +0.30Society for Immunotherapy of Cancer 0+1 entities
2026-10-02 07:06:51 UTC#403663newconfirmednews
3D Investment Partners reduces stake in MediciNova to 9.88% from 11.22%
2026-10-01 23:00:00 UTC#402342updateconfirmednews
Medicenna Therapeutics (MDNA) shareholders approve 1-for-2 to 1-for-20 reverse stock split
2026-09-28 11:15:00 UTC#376983newconfirmednews
MediciNova shares drop 13% as MN-001 Phase 2 trial fails to meet liver fat reduction endpoint
2026-09-24 11:06:45 UTC#361829newconfirmedpress release
Medicenna to present bizaxofusp survival data in recurrent glioblastoma at 2026 SNO Annual Meeting
financial postimportance 0.40trust 0.90Medicenna Therapeutics Corp. +0.40bizaxofusp +0.40Society for Neuro-Oncology 0
2026-09-24 10:00:00 UTC#361390newconfirmedpress release
MediciNova completes double-blind portion of Phase 2b/3 COMBAT-ALS trial for MN-166
2026-09-16 19:38:16 UTC#323251duplicateconfirmednews
Medicenna Therapeutics reiterates upcoming clinical data milestones for MDNA11 and bizaxofusp
2026-09-11 11:48:17 UTC#298251newconfirmednews
Medicenna Therapeutics (MNOV) expects MN-001 metabolic data in September and COMBAT-ALS results by year-end
2026-09-02 11:33:02 UTC#255202newconfirmednews
MediciNova terminates $30M Yorkville standby equity facility with no fees or outstanding obligations
2026-08-19 11:33:01 UTC#194778newconfirmednews
MediciNova renews employment agreements for CEO Yuichi Iwaki and CMO Kazuko Matsuda
2026-08-14 11:04:14 UTC#177498newconfirmedpress release
Medicenna Therapeutics Reports Q1 Fiscal 2027 Results and Upcoming Oral Presentations for MDNA11 and Bizaxofusp
2026-08-13 22:41:04 UTC#175064newconfirmednews
MediciNova Inc Q2 adjusted loss $0.05/share vs $0.06 est, revenue $458K vs $50K est
2026-08-07 11:00:02 UTC#144490newforecastnews